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Summary
A murine class II major histocompatibility complex (MHC) heterodimer, Ek, expressed as a
glycan-phosphatidyl inositol-anchored chimera on Chinese Hamster Ovary cells, can present
peptides, but not processed antigen to T cells. This chimeric MHC requires a 100-times higher
peptide concentration to achieve a two- to four-times lower level of T cell stimulation. Cleavage
with phosphatidylinositol-specific phospholipase C and purification result in large quantities of
heterodimer in a water-soluble form. Plates coated with this material and then incubated with
peptide can efficiently stimulate the appropriate T cell hybridomas. This stimulation is significantly
enhanced when peptides are preincubated with the plate-bound MHC molecules in a pH range
(5.0-5.5) similar to that of late endosomes. More than half of the soluble Ek molecules can form
a specific complex with cytochrome c peptides in this pH range. This suggests that class II MHC
molecules undergo distinct conformational changes in endosomal compartments that render them
more capable of forming functional complexes with peptide antigens, irrespective of other cell
components.
T
lymphocytes, through their specific antigen receptors,
recognize fragments of foreign antigens complexed to
molecules of the MHC. Class I MHC molecules appear to
present peptides from endogenously synthesized proteins,
whereas class II molecules present peptides derived from pro-
teins that have been endocytosed and degraded (1, 2) .
Numerous examples have been documented demonstrating
binding ofspecific synthetic peptides to isolated classII MHC
molecules, resulting in the formation of functional complexes
that can be recognized by T cells (3-8). One discrepancy
emerging from these studies is that peptide uptake and MHC
presentation in vivo are more efficient than can be accounted
for by the relatively slow ratesofpeptide/MHC complex for-
mation observed in vitro (9). Another problem is that the
amount ofMHC capable ofbinding exogenous peptide seems
very limited (1-20%) (8), presumably due to the presence
of endogenous peptides (10). One way to account for these
anomalies is to postulate a role for accessory molecules, which
might enhance peptide uptake (11). Alternatively, Jensen (12)
has shown that class II MHC-bearing cells that have been
fixed with paraformaldehyde can stimulate T cell hybridomas
more efficiently afterincubation with peptides at weakly acidic
pHs (4.5-5.5; approximating those of the late endosomal and
lysosomal compartments ) (13) . As class II MHC molecules
are known to traverse the endosomal compartments (14-17),
and at least in some cells seem to be recycled an average of
60 times (18, 19), it is possible that some or all of the dis-
crepancies observed between in vivo antigen presentation and
the binding of antigen to purified MHC in vitro might be
explained by passage through an acidic environment. Since
the experiments cited involved fixed cells (12), other expla-
nations for this effect are also possible, including bystander
molecules and lipid interference or cooperativity.
In our studies, we have been interested in expressing mouse
class II MHC molecules in a soluble form in order to study
their interactions with peptides and with cognate TCR mol-
ecules under detergent-free conditions. We report here a
strategy for doing so using the signal sequences for lipid-
linked expression derived from humanplacental alkaline phos-
phatase (HPAP),1 which we have defined and successfully
used to express a TCR heterodimer (19). Ek molecules ex-
pressed in this glycan-phosphatidyl inositol (GPI)-anchored
1 Abbreviations used in this paper: CPB, citric acid phosphate buffer; GPI,
glycan-phosphatidyl inositol; HPAP, human placental alkaline phosphate;
MCC, moth cytochromec; n, native; PCC, pigeon cytochromec; PI-PLC,
phosphatidylinositol-specific phospholipase C.
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Volume 174 July 1991 219-228form areefficiently removed from thecell surface with as
enzyme, phosphatidylinositol-specific phospholipase C (Pl-
PLC) (20). Cells bearing lipid-linked (pi) Ek canpresent pep-
tide antigens to most T cell hybridomas with an apparent
fine specificity that is indistinguishable from wild-type Ek
molecules. In contrast, they are unable to present a whole
antigen efficiently, indicating that either the efficiency ofcel-
lular uptake of exogenous antigens is affected, or that the
chimeric MHC molecule does not traverse the same com-
partments as the normal molecule. Of particular relevance
to the questions discussed above, we have developed a new
assay for antigen presentation to T cell hybrids, using tissue
culture plates coated with purified PI-PLC-solubilized Ek
and a standard IL-2 assay. Using this assay, we have shown
that functional antigen/MHC complexes are formed more
efficiently at endosomal pHs (5 .0-5.5) than at neutral pH.
This indicates that at least part of the discrepancy between
the in vivo antigen presentation results and binding of pep-
tide to purified class II MHCmolecules lies in thelatter being
more efficient at these lower pHs. We have also used this
finding to generate specific peptide-MHC complexesat high
efficiency (> 50%), which will allow a wide range of phys-
ical studies to be possible.
Materials and Methods
Constructs.
￿
DNA encoding HPAP residues 476-513 (21) was
cloned into plasmid Bluescript SK- (Stratagene), as described (19).
Full-length Ek a and (3 chain cDNAs (22) were cloned into the
same vector 5' of the HPAP sequences. Ek/HPAP in-frame chi-
meric constructs were then produced using site-directed mutagen-
esis (23). Correctfusions wereconfirmedbyDNAsequencing using
the SequenaseSequencing Protocol (US. Biochemical Corp., Indi-
anapolis, IN). The fusedinsertsfor theaand(3 chains were cloned
into the eukaryotic expression vector pBJ-Neo in the fashion de-
scribed for TCR a and /3 chains (19). The resulting construct is
called pBJ1-Neo/MHCa0.
Oligonucleotides.
￿
The oligonucleotides used to create the chi-
meras were as follows: a, 5'-G000GCGGGGGGCGCCAGG-
AGGAGGGTTTTCTC;01, 5'-GCCGGCGGGGGGCGCCAGT
GTGGACTGTGCTTTC; X32, 5'-000GGCGGGGGGCGCCAG-
CTGTGCAGATGTGGAC. Synthesis was carried out on a DNA
synthesizer (380B; AppliedBiosystems, Inc.) (Oligonucleotide Ser-
vice Center, Dept . of Cell Biology, Stanford).
Transfections.
￿
5 x 106 CHO cells were trypsinized, washed,
and resuspended in 0.5 ml Ix HeBS (24) containing 5 ug pBJ1-
Neo/MHC-a/,Q linearized at the unique vector Aat II site. Trans-
fectionwasby electroporationusing aGene Pulser (Bio-Rad Labora-
tories) set to 500 AF and chargedat 230 V forpulse delivery. Cells
were iced 10 min before and afterelectroporation, andthen plated
as apool. 36 haftertransfection, G418 was brought to 0.5 mg/ml
(active drug) and resistant cells were carried as a heterogeneous
culture.
FACS® Analysis/Cloning.
￿
For FACS® analysis (Becton Dick-
inson & Co., Mountain View, CA) adherent cells were brought
into suspension by treatment with 5.3 mM EDTA in PBS and
washed. Cells were stained with the following mAb reagents in
theorder: Y17(25) (gift of PJones), goat anti-mouse FITC (Sigma
Chemical Co., St. Louis, MO), biotin-conjugated 14-4-4 (26) (gift
ofI. MacNeil) with 1% normal mouse serum, andavidin-conjugated
allophycocyanin (biomeda) or PE (biomeda). FACS®analyses were
220
￿
Soluble Class 11 Major Histocompatibility Complex
performedessentially as described (27). For FRCS® cloning G418-
resistant cells were stained as above and single cells from the ap-
proximately brightest staining 5% were sorted into microtiter wells,
expanded, and rescreened by FACS® analysis.
Plate Activation andLymphokine Release Assays.
￿
I1,2 assays were
carried out essentially as previously described in RPMI 1640 sup-
plemented with 10% FCS, 50 E,M /3-mercaptoethanol, 2 mM
L-glutamate, 100U/ml penicillin, and 100 /4g/ml streptamycin (28).
Briefly, 10s APC, antigen, and antibody (as described in each
figure), and 10s 2B4.11A cells or Jurkat 2B4 (Patten, P.A., E.P.
Rock, T Sonoda, B.Fazekasde St. Groth, andM.M. Davis, manu-
script submitted for publication) were added to microtiter wells
in a final volume of 0.2 ml for 16-24 h at 37°C. 2B4.11A was de-
rived from 2B4 by recloning and then screening for a high IL-2
producer. For plate activations with soluble MHC, 0.05 ml of 10
P,g/ml soluble Ek in PBS was incubated at 4°C overnight to coat
microtiter wells (Immunolon 4plates;Dynatech Laboratories), after
which antigen was added at various pHs in McIlvaines citric
acid-phosphate buffer system (CPB) (29), and allowedto incubate
for 24 h at 37°C. The wells were then washed twice with 1%
FCS/RPMI 1640, and T cellswere added in RPMI supplemented
with 10% FCS, and otheringredients, as described above. Super-
natants from activation wellswere analyzed for IL-2 by culturing
serial dilutions of each (0.05 ml) with 4 x 103 HT-2 cells (0.05
ml) (30). After 22 h at 37°C, wells were pulsed with 1 1Xi of
[3H]thymidine and incubated for another 4 h at 37°C, after which
[3H] incorporation was determined. 1 U/ml of IL-2 was defined
as theconcentration at whichhalf-maximal incorporation occurred.
The11,2 data from astandard andfrom test supernatants was simul-
taneously fitted with a four-parameter logistic curve using the
ARCUS RADIMM program (adapted from Dr. D.J. Finney by
Dr. Tony Kyne) to calculate the 11,2 activities.
Peptides.
￿
Peptides (kindly provided by C. Turck) used in the
T cell activation assays were as follows: PCC 81-104, IFAGIK-
KKAERADLIAYLKQATAK; MCC 83-103, biotin-AGIKK(K)
ANERADLIAYLKQATK; MCC 88-103, ANERADLIAYLK-
QATK; MCC 88-102, ANERADLIAYLKQAT MCC 87-103,
biotin-KANERADLIAYLKQATK . MCC 83-103 has an additional
lysine residue (K)as indicated, dueto aclerical error(M.M.Davis).
This does notseem to affect either MHCbindingor Tcell stimula-
tory activity, however. Peptide controls (kindly provided by T
Mietzner) forbindingstudieswere as follows: OVA323-339ISQAV
HAAHAEINEAGR; HEL 46-61 NTDGSTDYGILQINSR.
Whole Cytochrome c Assays. IL3 assays were carried out as
follows. 5 x 104 5C.C7 T cells and 5 x 10" native (n) El or r
Ek APCs were incubated in dilutions of PCC protein (Sigma
Chemical Co.) or MCC 83-103 in 200p,l 10% FCS/RPMI 1640
in microtiter plates at 37°C. PCC protein andMCC peptide were
purified on C-18 reversephaseHPLC using an acetonitrile gradient
in 0.1% TFA. After 24 h, the supernatant was assayed for 11,3
activity using the indicator cell line R6X (31). 5 x 103 cells were
incubated in 100 Al in a microtiter plate containing supernatant
dilutions. After 42 h, the cells were pulsed with 1 pCi [3H]thymi-
dine for an additional 6 h. The cells were harvested onto glass
microfiber filters and [3H]incorporation was determined. 11,3 units
were calculated as described for IL2.
Affinity Purification ofSoluble Ek Molecules.
￿
Soluble El hetero-
dimers were purified from pi El cells as previously described for
GPI-linked TCR (19) with thefollowingdifferences. Thesuperna-
tant was brought to 5 mM EDTA, 1 mM PMSF, 1 jig/ml pep-
statin A, 1 lAg/ml leupeptin, pH 8 (NaOH), and 5 mM NaN3,
filtered, and then passed over a 14-4-4 affinity column (CNBr
Sepharose; Pharmacia Fine Chemicals, Piscataway, NJ). Thecolumnwas washed with PBS (pH 8) containing the above cocktail of in-
hibitors and 10% glycerol . Theelution buffer wasthesame as the
wash, except that 50 mM diethylamine, pH 10.5/0.15M NaCI
replaced the PBS . The eluate was neutralized with 1 M sodium
phosphate, pH 6.5 .
GelElectrophoresis.
￿
Protein sampleswere runon anonreducing
12% SDS-PAGE (32) gel for the visualization of peptide/MHC
complexes . Samples were loaded immediately on the nonreducing
gel without prior boiling. Protein bands were visualized by silver
staining (33) .
Protein Sequencing .
￿
An aliquot of affinity-purified soluble Ek
was precipitated with 10% TCA and then washed with acetone .
NHz-terminal protein sequencing ofthis material was carried out
in the presence of 1mg polybrene usinga protein sequencer(470A;
Applied Biosystems Inc.) with an on-lineHPLC (Protein and Nu-
cleic Acid Analytical Facility, Beckman Center, Stanford, CA).
Peptide Binding by ELISA .
￿
Soluble Ek at 500 nM was incubated
with 15 PM of the biotinylated peptideMCC 83-103 in CPB at
varying pH for 60 h at 37°C. Reactions were adjusted to pH 7
by addition of 2M Na2HP04 before addition of BSA to a final
concentration of2% (wt/vol) . To detect soluble Ek-associated pep-
tide, microtiter wells (DynatechLabs) were coated with rabbit an-
tiserum specific to the GPI "tail" by overnight incubation with
50 p.l of a 10 jaglml dilution in PBS at 4°C . After blocking of
nonspecific bindingby incubation with CPB containing2% BSA,
the binding reactions were "captured" for 90 min at room temper-
ature. MHC-associated peptide was detected using alkaline phos-
phatase-conjugated avidin (Vector Laboratories, Inc.), before de-
velopment with the 104 phosphatase substrate (Sigma Chemical
Co .) . A microplate reader (Molecular Devices) was used to mon-
itor optical density at 405 run, and this absorbance is directly propor-
tional to the percentage of soluble El molecules associated with
biotinylated peptide.
Peptide Binding for the Visualization of Peptide/MHC Com-
plexes . Soluble Ek at 740nM was incubated with a 10-fold or
100-fold molar excess of MCC peptides (MCC 83-103 or MCC
87-103) or a 100-fold molar excess of control peptides (I-Ad-
restrictedOVA 323-339 or I-Ak-restrictedHEL46-61) in CPB (pH
5.2) for20hat 37°C. Before SDS-PAGE, each sample was neutral-
ized by the addition of 2 M Na2HP04 . As additional controls,
MCC 83-103 was incubated with soluble Ek at a 10-fold excess in
CPB(pH7.0), andMCC 83-103 andMCC87-103 were incubated
together with soluble Ek at a fivefold excess of each in CPB
(pH 5.2) .
Results
Ek/HPAP Chimeric Constructs.
￿
To produce Ek molecules
in a solubleform, we replaced theCOON termini, including
the transmembrane regions, of both a and a chains with
a signal sequence for GPI linkage, as shown in Fig . 1 A .
Previous work had shown that a number of transmembrane
proteins can be expressed in this way (34, 35), and in our
own work, we have shown that the38COOH-terminalamino
acids of HPAP are sufficient to act as a signal sequence for
GPI linkage of a TCR heterodimer (19) . Two different Ek
/3 chain/HPAP fusions were constructed in order to increase
the likelihood that the two chains of Ek would be in the
proper register relative to each other to allow heterodimer
formation. One, designated E01/Pi, was made following the
same strategy applied in making Ea/Pi, lining up the two
sequences from the beginning ofthetransmembrane region.
The second, designated E02/Pi, was constructed using the
most COON-terminal cysteine as the point of referencebe-
tween the ce and ,Q chains . If the chimeric molecules are
processed in the same way as HPAP, then the aspartic acid
residue in the HPAP sequence will be both the 000H-
terminal amino acid residue of the processed chimeric pro-
teins (36) and thepoint at which these molecules arecoupled
to the membrane via the GPI moiety (37) .
Figure 1 .
￿
Chimeric Ek/HPAP a and 0 chain
constructs and expression in CHO cells . (A)
Schematic diagrams of theEk/HPAP single-chain
constructs showing the domain structure of each
chain and the sequences contributed by each pro-
tein . For Ek sequences, lettering begins with the
COOH-terminal half of the intrachain cystine
of the second domain . The 38 COOH-terminal
residues ofHPAP (HPAP-S) (19) are depicted, and
these were fused to each chain . The nine unboxed
residues of HPAP-S are those that are predicted to
remain in the chimeric chains after formation of
theGPI linkage (36) . Standard amino acid single
letter abbreviations are used. (B) G418-resistant
CHO transfectants were stained with anti--a chain
(14-4-4)vs. anti-O chain (Y17)mAbs. As indicated
in the figure, the four samples areCHOuntrans-
fected (CHO), CHO transfected with Ea/Pi and
Ell/Pi (pi Ek [unsorted]), a clone derived from
the latter (pi Ek), and a clone derived from n
Ek-transfected CHO (n Ek) .Chinese Hamster Ovary (CHO) Ek1HPAP Transfectants.
CHO cells were used as the recipients of Ek/HPAP chimeric
constructs. The cells were transfected with Eot/Pi and either
E(31/Pi or E02/Pi inserted together into pBJ1-Neo (as de-
scribed in Lin et al. [19]), and selected for G418 resistance.
The native a and (3 chain cDNAs were also inserted into
pBJ1-Neo and transfected into CHO cellsfor use as controls.
Cells that survived selection were analyzed by staining with
anti-Ea and anti-E/3 mAbs, and the FACS`0profiles are shown
in Fig. 1 B (secondpanel). The initial sample of G418-resistant
(pi Ek) cells analyzed originated from a pooled transfection
and contained two populations of cells, one staining brightly
and one weakly. The cellswere positive for both chains, with
a diagonal pattern of staining indicating that for any given
cell, the amount of a chain staining is comparable with that
of the 0 chain. This suggests that only Ek a/O heterodimers
are expressed on the cell surface, unlike the case ofTCR GPI
chimeras, where monomers are also expressed (19). This in-
terpretation is consistent with the fact that cells transfected
with only one GPI-linked Ek chain are negative for cell sur-
face expression (data not shown). Thus, it appears that only
heterodimeric Ek structures can be stably expressed. Treat-
ment with PI-PLC removes 80-90% of the surface staining,
indicating that most or all molecules are GPI linked (data
not shown). Subsequent cell cloning resulted in homogene-
ously high expressing, stable cell lines for both GPI-linked
Ek (Fig. 1 B, third panel) and for clones expressing a similar
amount of native Ek (Fig. 1 B, fourth panel) for use as a con-
trol (see below).
Antigen Presentation by Cells Expressing GPI-linked El.
￿
To
evaluate the functional properties of the chimeric molecule,
we performed lymphokine release assays using the pi Ek cells
to present antigen. As a control, we used a CHO cell clone
transfected with Ek ot and a chains. As a T cell responder,
we used the cytochrome c-specific, I-Ek-restricted T cell hy-
bridoma 2B4 (38, 39). Fig. 2 shows the dose-response curves
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Figure 2.
￿
Activation of T cells by APC bearing native or GPI-linked
Ek. Antigen dose-response curves using, as antigen presenters, the native
Ek-bearing CHO clone (n Ek) or the GPI-linked Ek-bearing clone (pi Ek)
shown in Fig. 1. The peptides used are MCC 88-103, and PCC 81-104.
Theresponder cell is 2B4.11A. Error bars represent population SD oftripli-
cate values.
for IL -2 production. Although markedly less effective at
stimulating 2134 at low concentrations of peptide than n Ek
cells, the pi Ek cells can stimulate 2114 to make to make large
quantities of 1172. In addition, the moth cytochrome c (MCC)
peptide 88-103 is more potent than the pigeon cytochrome
c (PCC) peptide 81-104, when presented by either cell line,
showing that the characteristic fine specificity of cytochrome
peptide presentation (40) is preserved with the GPI chimera.
The second chimera, made using Ex/Pi and E02/Pi, gave
essentially identical results (data not shown) . Of other Ek-
restricted peptides, hemoglobin admin 64-76 (41) and X
pi Ek MCCpeptide
n Ek MCCpeptide
nEk PCCprotein
pi Ek PCCprotein
Figure 3.
￿
Failure of pi Ek cells to
present whole antigen. Antigen dose-
response curves using, as antigen pre-
senters, the same clones mentioned in
Fig. 2. APC were incubated with ei-
ther PCC protein or MCC peptide
83-103 to stimulate the T cell clone
5C.C7. Shown is oneof two indepen-
dent experiments with similar results.
Error bars denote the 95% confidence
interval.repressor 12-26 (42) could also be presented by the pi Ek
cells to specific T cell hybridomas, while hen egg white lyso-
zyme 85-96 (43), could not (data not shown). Thus, three
of four peptides can be presented on both GPI-linked Ek and
Ek molecules, but the effectiveness of stimulation by the
GPI-linked molecule is significantly reduced (50-100-fold),
and the plateau levels of 11,2 release are somewhat lower (two-
to fourfold). Since most pi El molecules can bind peptides
specifically (see below), and the ability of cells bearing these
molecules to present antigen is removed by PI-PLC treatment
(data not shown), the explanation for this phenomenon seems
to lie in the more flexible nature of the GPI linkage vs. a
transmembrane form of attachment (see Discussion).
We also tested the ability of the pi Ek-bearing cells to
present intact protein. For this assay, we used the IL-3-
producing cytochrome c-specific, Ek-restricted cell line
5C.C7 (44), because the detection threshold is -100-fold
lower than the 11,2 assay with 2B4. McCoy et al. (45) have
shown that Ek-bearing CHO cells can process and present
whole cytochrome c. As shown in Fig. 3, a response to whole
PCC is detectable at 0.3 AM, but no response is visible at
even 400 AM with the pi Ek cells. Peptide stimulations with
the two cell lines are included as controls. Since it is clear
that CHO cells can process cytochrome c and transfer the
antigenic peptide(s) to native Ek, it appears that pi Ek is
deficient in this regard.
The SolubleEk Is Heterodimeric.
￿
A high-expressing clone
of pi Ek cells was selected and grown to confluence in a
hollow-fiber bioreactor (Cell Pharm, Unisyn Fibertech) . Peri-
odic treatment with PI-PLC as described (19) results in 0.2-0.5
mg/harvest of soluble Ek (see Materials and Methods). To
determine whether the a and a chains are noncovalently as-
sociated with each other as in the native state, we analyzed
a sample ofaffinity-purified chimeric protein on nonreducing
SDS-PAGE. The soluble Ek migrates with an apparent mass
of 65-70 kD (see below), consistent with it being a hetero-
dimer. Additionally, NHz-terminal sequencing of the affinity-
purified protein revealed three distinct species (Fig. 4), one
of which is the a chain, (46) and two of which are a chain
sequences (f and a') (47) . Whereas the a sequence began
as expected, the ,0 sequence began one amino acid previous
to the start ofthe mature protein purified from mouse spleen
cells (P. Jones, personal communication) . The a' sequence
corresponds to the 0 chain sequence beginning at the third
amino acid of the mature Ek-a polypeptide. The a and (3
sequences are present in roughly equimolar amounts, and they
constitute the majority of the sequencing yield, with the 0'
Figure 4. NH2-terminal se-
quence of cleaved GPI-linked Ek.
Multiple amino acid residues were
detected at each round of NH2
terminal protein sequencing (three in rounds 1 and 3-7; two in the rest).
Using available sequence information, the protein sequencing data could
be arranged as an a chain and two 0 chain sequences. The minor 0' se-
quence derives from data obtained in rounds 1-8, but is aligned with the
0 sequence to show their correspondence (see text). The hyphen indicates
absence ofsequence information. Standard single letter amino acid abbrevi-
ations are used.
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sequence accounting for -10% of the yield. A difference of
10% in the amount ofa vs. a chain would not be detectable.
As the affinity purification of Ek used only 14-4-4, an anti-
Ea-specific antibody, the presence of the 0 chain is a further
indication that GPI-linked Eat and GPI-linked Ef are non-
covalently associated during expression and purification.
Activation of T Cells With Soluble El. To determine
whether the purified soluble Ek obtained above is still func-
tional, the purified protein was substituted for APC in a lym-
phokine release assay (Fig. 5). Microtiter trays (Immulon 4)
were coated with 10 Fig/ml soluble Ek, incubated with pep-
tide, washed, and then T cells were added to the wells (see
Materials and Methods). When soluble Ek-coated plates are
incubated with MCC 88-103, this combination alone stimu-
lates 2B4 cells. As shown in Fig. 5, activation was not de-
tected in the absence of this peptide or in the presence of
MCC 88-102, an inactive variant (48). Activation was com-
pletely blocked with the 14-4-4 antibody. Thus, soluble class
II MHC bound to plastic exhibits the same antigen specificity
and activation characteristics as cell-bound MHC, with no
requirement for a lipid environment. This has previously
been shown for detergent solubilized class I MHC by Kane
et al. (49).
The simplicity of this assay provides a convenient means
ofoptimizingthe formation offunctional antigen/MHC com-
plexes. Because ofJensen's previous work with fixed cells (12),
we were particularly interested in deriving a pH optimum
for peptide/MHC formation by incubating Ek-coated plates
with 100 AM peptide at different pHs for 24 h at 37°C. Free
peptide was washed away and the plates were incubated with
specific T cell hybridomas. Fig. 6 A shows the results for
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Figure 5.
￿
Activation of T cells by soluble Ek bound to plates. Soluble
Ek was used to coat microtiter wells and then incubated with the indi-
cated peptide in 1x PBS and/or blocking antibody. Wells were washed
twice and then 2B4.11A T cells were added and 11,2 release assayed as
described in Materials and Methods. MCC 88-102 lacks the 000H-
terminal lysine residue. The mAb 14-4-4 was used at 2 Fag/ml. The dotted
line marks the assay limit of sensitivity.G
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Figure 6.
￿
Enhanced T cell activation at low pH. Soluble Ek coated on microtiter wells and incubated with peptide over a range of pHs was used
to activate T cell hybridomas. (A) pH titration of MCC 88-103 as assayed by 2B4.11A stimulation. (B) pH titration of hemoglobin Gamin 64-76 as
assayed by Y01.6 stimulation. Error bars represent the population SD of triplicate values.
a moth MCC peptide and the 2B4 hybridoma. In this case,
there is a clearoptimum slightly higher than pH 5.0, leading
to an 1162 release that is four times the value of that obtained
at neutral pH (7.3). The same analysis using hemoglobin
admin 64-76 and the T cell hybridoma (41) YO1.6 gave
similar results (Fig. 6 B) with the optimum at pH 5 .0. These
results are similar to those obtained byJensen (12), suggesting
that much or all of the effects seen in that report, involving
peptides restricted to Ad as well as Ed, may be attributed to
class II MHC molecules and specific peptides alone. Other
parameters, such as salt concentration (0.1-2.0 M), or addi-
tion of lipids (5 mM lysophosphatidylserine) (50) during the
peptide incubation had no effect (data not shown).
Highly Efficient Formation of Peptide/E' Complexes at Low
pH. To investigate whether the low pH optimum seen in
the activation assay was associated with enhanced pep-
tide/MHC complex formation, we directly measured the pH
dependency of antigen/El complex formation in solution,
using a biotinylated cytochrome peptide (MCC 83-103) and
a "capture" ELISA using antibodies directed at the GPI tail
(Reay, P., et al., manuscript in preparation). As shown in
Fig. 7, a pH curvevery similar to the T cell activation curve
of Fig. 6 A was observed, with an optimum at pH 4.8-5 .0.
Thus, the enhanced T cell stimulation correlatesprecisely with
increased peptide binding to the soluble Ek protein. To
visualize this complex directly, we also incubated two different
lengths of MCC peptide (MCC 83-103 and MCC 87-103)
with Ek for 20 h at pH 5.2, using either a 10-fold or 100-
fold molar excess of peptide. When assayed on nonreducing
SDS-PAGE gels, Ia heterodimers stay largely intact (51). As
shown in Fig. 8, lane 2 soluble Ek runs as a diffuse hetero-
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dimer but resolves into a more distinct band when incubated
with either ofthe cytochrome peptides (lanes 3-6). The diffuse
nature of the heterodimer band in the absence ofbound MCC
peptide may be due to the presence of endogenous peptides,
which results in a heterogenous population of MHC mole-
cules. Either of two irrelevant peptides (OVA 323-339 and
HEL 46-61), which are restricted to other class II MHC mol-
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Figure 7,
￿
Enhanced peptide binding at low pH. Soluble Ek was in-
cubated with the biotinylated peptide MCC 83-103 at the pH indicated
for 60 h at 37°C. Samples were neutralized to pH 7, and the amount
ofbiotin associated with Ek was determined (see Materials and Methods).ecules (Ad and Ak, respectively), fail to cause an intensi-
fication or shift in the Ek heterodimer band (Fig. 8, lanes
7 and 8), nor can they inhibit this band sharpening when
co-incubated with either MCC peptide (data not shown) .
Also indicative of specific complex formation is the differ-
ence in mobility between the two cytochrome peptide/MHC
complexes, with the longer peptide showing reduced mo-
bility (70kD) vs . the shorter (65 kD) . Although this differ-
ence in apparent mobility ismuch more than one could nor-
mally attribute to the additional five amino acids in the
peptides, the longer peptide likely protrudes some distance
outside the binding site and thus might disproportionately
alter the radius of the complex . When both peptides are in-
cubated with Ek, both bands are visible (Fig. 8, lane 9) . In-
cubation of one of these same peptides (MCC 83-103) with
Ek at pH 7.0 (lane 10) results in a less distinct heterodimer
band, consistent with previous reports that only 1-20% pep-
tide/MHC complexes can be formed at neutral pH (5,3), and
our own results summarized in Figs . 6 and 7 . The amount
of biotinylated cytochrome c peptide (MCC 83-103) speci-
fically complexed with soluble Ek was assessed using fluores-
cence enhancement of fluorescein-labeled streptavidin (52) .
Using the enhancement of fluorescence by known concen-
trations of free biotinylated cytochrome c peptide (MCC
83-103) to generate a calibration curve,we estimate that 60%
of the soluble Ek molecules are occupied by MCC 83-103
at pH 5 (data not shown) .
Discussion
The chimeric Ek/HPAP molecule described here is clearly
functional with respect to a number of peptide/T cell com-
binations and has significant advantages over other approaches
for studying class IIMHC molecules . Large quantities (1-3
mg/wk) of protein can be produced continuously from one
bioreactor in a water-soluble form, without the need for de-
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Figure 8 .
￿
Visualization ofpeptide/MHC complexes by
SDS-PAGE . Soluble Et was preincubated in the absence
of peptide (lane 2) or in the presence of a 10- or 100-fold
molarexcessofMCC 83-103 (lanes3 and4),MCC 87-103
(lanes 5 and 6), or a fivefold excess of each (lane 9) atpH
5.2, 37°C for 20 h . Also shown are the results ofpreincu-
bations with a 100-fold excess of the I-A-restricted pep-
tidesOVA 323-339 (lane 7) orHEL 46-61 (lane8), under
the same conditions as above, or with a 10-fold excess of
MCC 83-103 (lane 10) at pH 7 .0 . All samples but the
latter were neutralized before SDS-PAGE .
tergents. This is important because even mild detergents can
interfere with protein-protein interactions . In particular, the
earlier failure to see enhanced peptide binding to detergent-
solubilizedMHC molecules at lowpHs (5) may well be due
to detergent effects. Fraser (53) has also reported changes in
staphylococcal enterotoxin B binding to class IIMHC mole-
cules purified by detergent solubilization vs . surface mole-
cules . The advantage of the methodology described here over
existing procedures to prepare soluble class II molecules by
papain cleavage (54) is that harvesting conditions are gentler
(papain may cleave elsewhere), and the use ofcDNA trans-
fectants makes the introduction of modifications easier. Thus
far, the papain cleavage procedure has been limited to existing,
high-expressing cell lines ofhuman origin, and the solubi-
lized protein has not been tested for its capacity to stimulate
T cells (although it can bind specific peptide antigens) (8) .
Peptides generated by endogenous processing ofcytochrome
c are available to Ek expressed in CHO cells, but not (or very
poorly) to GPI-linked Ek expressed inCHO cells, indicating
that the chimeric molecules are not treated as native mole-
cules by the recipient cells . The most likely explanation for
this is that the GPI anchor does not direct them to the en-
dosomal compartment . A T cell receptor/HPAP chimera
reported previously (19) transits from the Golgi apparatus
to the surface ofCHO cells without any detectable expres-
sion in endosomal or pre-endosomal vesicles (R . Klausner,
personal communication) . One use of the chimera described
here is that it may allow the identification and isolation of
ubiquitous allo- and autoantigens from cell extracts for which
there is no other specific assay.
Although the pi Ek cells are not as effective at presenting
peptides as are cells bearing equal numbers of native mole-
cules, the soluble Ek is highly stimulatory in the plate assay
(Figs. 5 and 6), and most of the soluble Ek molecules are
able to bind peptides specifically (Fig. 8) . The kinetics of pep-
tide binding at neutral pH (Reay et al ., manuscript in prepa-ration) are also very consistent with published values for a
cytochrome c peptide (55). We have also examined the ki-
netics of the biotin-labeled peptide (MCC 83-103) binding
to GPI-linked Ek and Ek on cells, and find them indistin-
guishable (data not shown). Thus, there appears to be no
difference in the peptide binding ability of the GPI-linked
and native forms of Ek . Rather, it seems likely that the
"floppiness" of the GPI anchor (vs. the more rigid trans-
membrane-anchored form) might cause fewer or less effec-
tive antigen/Ek complexes to be available for binding to
TCRs. The failure of pi Ek cells to present peptides to some
T cell hybrids may be due to differences in glycosylation be-
tween the Ek/HPAP and n Ek biosynthesis pathways. Per-
haps most importantly, the work here confirms and extends
that of Jensen (12) to indicate that endosomal pHs can
significantly enhance the formation of specific peptide/MHC
complexes as judged by both T cell reactivity and formation
of specific peptide/heterodimer complexes (Figs. 6, 7, and
8) . One difference between our results and those ofJensen
(12) is the magnitude of the pH effect on T cell stimulation.
He reports 5-15 times differences at analogous peptide con-
centrations (Fig. 1 of reference 12), whereas we see a three
to four times effect. This may reflect the greater sensitivity
of a fluidmembrane environment (fixed cells in his case), where
every MHC molecule is in the correct orientation and groups
of molecules can form hyper-stimulatory patches. As shown
by Jensen (12) for four different peptides restricted to two
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